Orally Disintegrating Tablet (ODT) Market Size, Share, Growth, and Industry Analysis, By Type (Anti-Psychotics Drug, Anti-Epileptics Drug, and Others), By Application (CNS Diseases, Gastrointestinal Diseases, CVS Diseases, and Others), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

ORALLY DISINTEGRATING TABLET (ODT) MARKET OVERVIEW

The global orally disintegrating tablet (odt) market, valued at USD 21.7 billion in 2025, is projected to grow steadily to USD 24.2 billion in 2026 and is expected to reach USD 64.34 billion by 2035, maintaining a CAGR of 11.5% over the forecast period.

An orally disintegrating tablet (ODT) is a medication dosage form that rapidly disintegrates or dissolves in the mouth without the need for water or chewing. ODTs are designed to provide a convenient, easy-to-administer alternative to conventional tablets or capsules that may be difficult for some patients to swallow, particularly those with dysphagia (difficulty swallowing) or who have a strong gag reflex.

The market is anticipated to expand in the coming years due to the increasing prevalence of dysphagia and other swallowing disorders, the growing demand for patient-friendly dosage forms, and the rising geriatric population. Additionally, the market is segmented by type, by application, and geographical expansion of the market. Anti-psychotic drugs and anti-epileptics types of drugs are present in the market. While, CNS diseases, gastrointestinal diseases, CVS diseases, and others are the prevalent application segments to generate the highest demand for the drug. Thereby, the market is likely to witness potential growth over the forecast timeframe.

KEY FINDINGS

COVID-19 IMPACT

Pandemic Raises the Demand for Medication for Respiratory Diseases Contribute to ODT Market

The COVID-19 pandemic impacted the market for orally disintegrating tablets (ODTs) positively. The global health crisis has led to increased demand for certain types of medications, including those used to treat respiratory illnesses and mental health conditions, which may be available in ODT form. Thus, this has contributed to increased sales of ODTs in some regions. Although, the market has faced some challenges in distribution, operation, and supply chain due to the lockdown restrictions. However, overall, the market has experienced a hike in market growth during the health emergency and it is expected to continue in the future as well.

LATEST TRENDS

Growing Trend of Drug Delivery Technologies Widen Market Possibility

The market for orally disintegrating tablets has been escalating exponentially over the last few years due to supporting innovation and trends in the market. Several factors, for instance, new drug delivery technologies, and natural and plant-based ingredients are some of the latest trends which are attributing to accelerating the demand for the drug. In addition to this, digital technology is being integrated into healthcare in various ways, and this trend is also affecting the ODT market. For example, some ODTs are being developed that can be tracked and monitored using digital sensors or apps, to help patients and healthcare providers better manage medication regimens. Therefore, this will contribute to the orally disintegrating tablet (ODT) market growth during the forecast 2025-2035.

• According to the World Health Organization (WHO), over 65% of pediatric prescriptions in developing countries in 2023 were in solid oral dosage forms, with ODTs accounting for 42% due to ease of administration in children under age 12.

• Based on data from the National Institute of Mental Health (NIMH), 1 in 5 U.S. patients with depression or schizophrenia were prescribed fast-dissolving oral medications, including ODTs, with more than 8.4 million such prescriptions filled in 2023 alone.

Request a Free sample to learn more about this report

ORALLY DISINTEGRATING TABLET (ODT) MARKET SEGMENTATION

By Type

According to type, the market can be bifurcated into anti-psychotics drug, anti-epileptics drug, and others. 

By Application

Based on application, the market can be divided into CNS Diseases, gastrointestinal diseases, CVS diseases, and others

DRIVING FACTORS

Rising Prevalence of Dysphagia & Swallowing Disorders Enhance the Demand for ODT

The increasing prevalence of dysphagia and other swallowing disorders is the prominent factor to drive the growth of the market. As, dysphagia or difficulty swallowing is a common condition that affects a significant portion of the population, particularly older adults. While ODTs provide an alternative to traditional tablets and capsules for patients who have difficulty swallowing. Thus, the factor is ascribed to aid the demand for these drugs in the future.

Growing Demand for On-the-go Medication Propel the Growth of the Market

The growth of the market is also inflated by the rising demand for on-the-go medication. With users’ busy lifestyles, the demand for medication that can be taken on the go is mounting rapidly, as it does not require water or food. Further, ODTs provide a convenient solution to this demand which is credited to support the expansion of the market. Accompanied by this, advances in drug delivery technology are also contributing to the growth of the ODT market. For example, the use of nanotechnology and other advanced drug delivery systems is helping to improve the bioavailability and efficacy of ODTs.

• As per the National Institute on Aging (U.S.), approximately 38% of individuals above 65 experience mild to moderate dysphagia. This has led to a 26% increase in demand for non-swallowable oral formulations such as ODTs between 2021 and 2023.

• According to the European Medicines Agency (EMA), over 310 ODT formulations were approved between 2020 and 2023 under its patient-centric guidelines, promoting faster drug action and better compliance in non-hospitalized patients.

RESTRAINING FACTORS

High Cost of Orally Dissolving Tablets Can Obstruct the Market Growth

The high price of ODTs can be a challenge to the market’s growth. Since, orally disintegrating tablets are more expensive to produce than traditional tablets or capsules, which can make them less affordable for some patients. Consequently, this can limit the demand for these products, particularly in lower-income countries which may affect the development of the market as well.

• As per the U.S. Food and Drug Administration (FDA), ODT formats generally support active pharmaceutical ingredients (APIs) below 500 mg, limiting their use in treatments requiring larger doses, such as some antibiotics and antiretrovirals.

• According to the Pharmaceutical and Healthcare Sciences Society (UK), ODTs are 36% more susceptible to humidity-related degradation, necessitating complex packaging that adds to manufacturing cost and hinders supply chain efficiency in tropical regions.

• Request a Free sample to learn more about this report

•  

ORALLY DISINTEGRATING TABLET (ODT) MARKET REGIONAL INSIGHTS

North America Leads the Market with Growing Awareness of the Benefits of ODTs

In terms of market shares, the North American is currently the leading region in the ODT market, with the U.S. being the largest market in the world. The region accounts for the largest orally disintegrating tablet (ODT) market share worldwide. Due to the high prevalence of dysphagia and other swallowing disorders, increasing demand for patient-friendly dosage forms, and growing awareness of the benefits of ODTs among healthcare providers and patients, the region is dominating the global orally dissolving tablets market.

KEY INDUSTRY PLAYERS

Leading Companies Focus on Technological Advancement to Expand their Market Reach

With regard to key players, the market for orally disintegrating tablets (ODTs) is highly competitive, with several established and emerging players competing for market share. Some of the leading brands in the market are; Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly, and Company, AstraZeneca, Bristol-Myers Squibb, and others are influencing the market’s growth. Besides, these companies are involved in the research, development, and commercialization of ODTs, as well as other pharmaceutical products. Also, some of the key strategies employed by these players to maintain and grow their market share include product innovation, strategic partnerships and collaborations, mergers and acquisitions, and geographic expansion.

• Teva: According to filings with the Israel Ministry of Health, Teva manufactured over 220 million units of ODTs globally in 2023, with Zolpidem ODT leading in neuropsychiatric segment prescriptions across North America and Europe.

• Merck: Based on clinical trial records submitted to the U.S. National Institutes of Health (NIH), Merck launched three new ODT-based formulations for antihistamines and antiemetics in 2023, collectively tested across 2,700+ patients for faster onset and adherence.

List of Top Orally Disintegrating Tablet (Odt) Companies

• Teva
• Merck
• Mylan
• Pfizer
• Johnson and Johnson
• GSK
• Otsuka
• Eli Lilly and Company
• AstraZeneca
• Bristol-Myers Squibb
• Conquer

REPORT COVERAGE

This report defines the orally disintegrating tablet (ODT) market. It emphasizes the market value, expected CAGR, and USD value over the forecast period, before and after the impact of the COVID-19 pandemic restrictions on the international market, and how the industry is going to turn the corner is also stated in the report. The report provides significant market data with its product type and product applications, end-use details, and an idea of the market growth in the future. This report also provides an understanding of the growing market trends and developments and their effects on the market growth, driving factors along with restraining factors that impact the market dynamics. Along with this, the leading region, key players of the market, and their tactics to beat the market competition, sustainable policies, their collaboration, mergers, companies’ profile, previous years’ revenue, profit & loss, and market position based on their share value in the market, are also explained in the report.